肾移植患者骨转换标志物变化与骨密度变化的关联
本研究纳入209例肾移植患者,测量0、3、12个月骨转换标志物及0、12个月骨密度,发现骨密度年变化从-22%至+17%不等。移植时骨转换标志物较高且3个月内下降明显者骨密度增加,而标志物下降不明显或升高者骨密度丢失。3个月时标志物均未显著下降者,12个月骨丢失发生率几乎翻倍(69% vs 36%)。
要点
- 移植时高骨转换标志物且3个月内显著下降与骨密度增加相关
- 3个月时骨转换标志物未下降或升高与骨密度丢失相关
- 3个月标志物均未达最小显著变化者骨丢失风险更高
核心结论
- 肾移植后骨丢失高度可变,骨转换标志物下降反映高骨转换缓解,与骨密度增加相关,而标志物升高与骨丢失相关。
研究设计与样本
- 前瞻性队列研究,纳入209例肾移植患者,测量0、3、12个月骨转换标志物及0、12个月骨密度,49例有配对经髂骨活检。
主要发现
- 骨密度年变化范围-22%至+17%。
- 骨密度增加者移植时甲状旁腺激素236 vs 136 pg/ml、BALP 31.7 vs 18.8 μg/L、Intact PINP 121.9 vs 70.4 μg/L较高,3个月BALP下降-40% vs -21%、Intact PINP下降-43% vs -13%,12个月Intact PINP 36.3 vs 60.0 μg/L较低。
- 骨密度丢失者3个月Intact PINP变化+22% vs -13%、TRAP5b变化-27% vs -43%,12个月Intact PINP 83.7 vs 60.0 μg/L、TRAP5b 3.89 vs 3.16 U/L较高。
- 3个月时所有标志物均未达最小显著变化者,12个月骨丢失发生率69% vs 36%。
临床怎么用
- 肾移植后早期监测骨转换标志物变化,尤其是3个月时的下降幅度,有助于识别骨丢失高风险患者。
局限性
- 配对骨活检仅49例,样本量有限;观察性设计无法确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone loss after kidney transplantation is highly variable. We investigated whether changes in bone turnover markers associate with bone loss during the first post-transplant year. METHODS: Bone mineral density (BMD) was measured at 0 and 12 months, with biointact parathyroid hormone, bone-specific alkaline phosphatase (BALP), intact procollagen type I N -terminal propeptide (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP5b) measured at 0, 3, and 12 months post-transplant ( N =209). Paired transiliac bone biopsies were available in a subset ( n =49). Between-group differences were evaluated by Student's t test, Wilcoxon signed-rank test, or Pearson's chi-squared test. RESULTS: Changes in BMD varied from -22% to +17%/yr. Compared with patients with no change (±2.5%/yr), patients who gained BMD had higher levels of parathyroid hormone (236 versus 136 pg/ml), BALP (31.7 versus 18.8 μ g/L), and Intact PINP (121.9 versus 70.4 μ g/L) at time of transplantation; a greater decrease in BALP (-40% versus -21%) and Intact PINP (-43% versus -13%) by 3 months; and lower levels of Intact PINP (36.3 versus 60.0 μ g/L) at 12 months post-transplant. Patients who lost BMD had a less marked decrease, or even increase, in Intact PINP (+22% versus -13%) and TRAP5b (-27% versus -43%) at 3 months and higher Intact PINP (83.7 versus 60.0 μ g/L) and TRAP5b (3.89 versus 3.16 U/L) at 12 months compared with patients with no change. If none of the biomarkers decreased by the least significant change at 3 months, an almost two-fold (69% versus 36%) higher occurrence of bone loss was seen at 12 months post-transplant. CONCLUSIONS: Bone loss after kidney transplantation was highly variable. Resolution of high bone turnover, as reflected by decreasing bone turnover markers, associated with BMD gain, while increasing bone turnover markers associated with bone loss.
引用
- Jørgensen HS, Claes K, Smout D, et al. Associations of Changes in Bone Turnover Markers with Change in Bone Mineral Density in Kidney Transplant Patients. Clin J Am Soc Nephrol. 2023. PMID: 38030558. doi:10.2215/CJN.0000000000000368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。